RCUS Arcus Biosciences, Inc.
Arcus Biosciences, Inc. (RCUS) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $1.5M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Azoy Alexander | Chief Accounting Officer | Sell 10b5-1 | 2,827 | $30.00 | $84.8K | 39,581 −6.7% of holding | |
| Jaen Juan C. 2 fills | President | Sell 10b5-1 | 20,067 | $28.62 | $574.3K | 822,508 −2.4% of holding | |
| Jaen Juan C. | President | Sell 10b5-1 | 48,502 | $30.05 | $1.5M | 842,307 −5.4% of holding | |
| Jaen Juan C. | President | Sell 10b5-1 | 6,431 | $29.66 | $190.7K | 890,809 −0.7% of holding | |
| Jaen Juan C. 2 fills | President | Sell 10b5-1 | 15,764 | $27.73 | $437.1K | 898,937 −1.7% of holding | |
| Jaen Juan C. | President | Sell 10b5-1 | 9,236 | $27.03 | $249.7K | 913,004 −1% of holding | |
| Azoy Alexander | Chief Accounting Officer | Sell 10b5-1 | 2,562 | $25.77 | $66.0K | 39,581 −6.1% of holding | |
| Goeltz II Robert C. | Chief Financial Officer | Sell 10b5-1 | 7,763 | $25.63 | $199.0K | 84,161 −8.4% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.